PIK3CB抗体;PIK3CB Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12054(PIK3CB Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P12054(PIK3CB Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PIK3CB antibody is a research tool targeting the p110β catalytic subunit of phosphoinositide 3-kinase (PI3K), encoded by the *PIK3CB* gene. PI3K enzymes regulate critical cellular processes, including growth, survival, and metabolism, by generating lipid secondary messengers that activate downstream effectors like AKT and mTOR. Unlike the ubiquitously expressed p110α (*PIK3CA*), p110β is implicated in both receptor tyrosine kinase (RTK) and G-protein-coupled receptor (GPCR) signaling, with distinct roles in PTEN-deficient cancers and platelet function.

PIK3CB antibodies are widely used in Western blotting, immunohistochemistry, and immunofluorescence to study p110β expression, localization, and activation in disease contexts, particularly cancer. Dysregulation of p110β is linked to tumor progression, metastasis, and therapy resistance, making it a potential therapeutic target. Selective inhibitors and isoform-specific antibodies (e.g., distinguishing p110β from p110α) are vital for dissecting its unique signaling contributions.

Validating PIK3CB antibody specificity is crucial, as cross-reactivity with other PI3K isoforms may occur. Knockout controls or siRNA validation are recommended. Research using these antibodies has advanced understanding of p110β's role in metabolic disorders, immune regulation, and combination therapies targeting PI3K pathways. Proper experimental controls ensure accurate interpretation of p110β's functional and clinical relevance.